Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: +$3.41M (14 inflow days, 6 outflow days).
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 47.0% of shares outstanding.
Reported short interest has risen from 16.34% to 17.73% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +374,478 | 0.2% |
| BlackRock | Mutual Fund | 2026/Q3 | +12,331,542 | 8.1% |
| Kynam Capital Management, LP | Hedge Fund | 2026/Q3 | +6,690,000 | 10.0% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +6,083,828 | 5.4% |
| Bank of America Corporation | Public Company | 2026/Q3 | +4,879,832 | 6.9% |
| Geode Capital Management, LLC | Mutual Fund | 2026/Q3 | +2,612,104 | 2.1% |
| Wellington Management Group | Mutual Fund | 2026/Q3 | +1,585,976 | 2.4% |
| Two Sigma Investments, LP | Hedge Fund | 2026/Q3 | +1,422,487 | 1.9% |
| Tudor Investment Corporation | Hedge Fund | 2026/Q3 | +1,380,687 | 0.6% |
| Northern Trust Global Investments | Mutual Fund | 2026/Q3 | +1,063,042 | 0.8% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +956,412 | 0.8% |
| FMR | Mutual Fund | 2026/Q3 | +759,300 | 15.0% |
| DV Equities, LLC | Mutual Fund | 2026/Q3 | +714,000 | 0.3% |
| Sphera Funds Management Ltd | Hedge Fund | 2026/Q3 | +659,000 | 0.4% |
| Goldman Sachs Asset Management, L.P. | Mutual Fund | 2026/Q3 | +603,298 | 0.3% |
Institutional buy/sell activity by reporting period, largest moves first.
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 2 Aug 2026 | Alejandra Carvajal | Chief Legal Officer | Other Acquisition | +100,000 | – | 100,000 |
| 2 Aug 2026 | Alejandra Carvajal | Chief Legal Officer | Other Derivative Acquisition | +450,000 | $3.17 | 450,000 |
| 23 Jul 2026 | Charles Fuchs | Former Independent Director | Other Derivative Acquisition | +118,000 | $3.24 | 118,000 |
| 16 Jun 2026 | Elaine Jones | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Mani Mohindru | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | James Meyers | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Matthew Young | Lead Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Halley Gilbert | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Alan Ashworth | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 16 Jun 2026 | Zhen Su | Director | Other Derivative Acquisition | +59,000 | $2.96 | 59,000 |
| 14 Jun 2026 | Christopher Ogden | Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer | Open Market Disposition | -1,624 | $3.05 | 128,075 |
| 16 Mar 2026 | Sean McCarthy | Chairperson & CEO | Open Market Disposition | -118,969 | $6.42 | 714,580 |
| 16 Mar 2026 | Yu-Waye Chu | Chief Medical Officer | Open Market Disposition | -21,279 | $6.42 | 39,613 |
| 16 Mar 2026 | Marcia Belvin | Senior VP & Chief Scientific Officer | Open Market Disposition | -31,492 | $6.42 | 164,927 |
| 16 Mar 2026 | Christopher Ogden | Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer | Open Market Disposition | -19,323 | $6.42 | 123,866 |
| 1 Feb 2026 | Sean McCarthy | Chairperson & CEO | Other Acquisition | +210,000 | – | 698,750 |
| 1 Feb 2026 | Sean McCarthy | Chairperson & CEO | Other Derivative Acquisition | +980,000 | $6.09 | 980,000 |
| 1 Feb 2026 | Rachael Lester | Chief Business Officer & Senior VP | Other Acquisition | +20,000 | – | 20,000 |
| 1 Feb 2026 | Rachael Lester | Chief Business Officer & Senior VP | Other Derivative Acquisition | +50,000 | $6.09 | 50,000 |
| 1 Feb 2026 | Yu-Waye Chu | Chief Medical Officer | Other Acquisition | +75,000 | – | 206,000 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Sep 2026 | 38,639,220 | 17.7% | 9.3 |
| 31 Aug 2026 | 33,512,293 | 15.4% | 11.8 |
| 14 Aug 2026 | 34,619,999 | 15.9% | 15.9 |
| 31 Jul 2026 | 35,110,952 | 16.1% | 11.8 |
| 15 Jul 2026 | 40,322,256 | 18.5% | 10.4 |
| 30 Jun 2026 | 35,567,462 | 16.3% | 4.3 |
No comments yet — be the first to weigh in on CTMX.